Why Spruce Point Capital Is Short Skechers: ‘30% To 50% Downside Risk To Share Prices’
Spruce Point Capital Management announced Tuesday that it is short shares of
Skechers U.S.A., Inc (NYSE: SKX).
Impel Commences Mid-Stage Autism Spectrum Disorder Study
Impel Pharmaceuticals (NASDAQ: IMPL) has dosed the first patient in a Phase 2a proof-of-concept study of INP105, nasal olanzapine, a widely used atypical, second-generation antipsychotic.
FDA Lifts Clinical Hold On Viking Therapeutics’ Rare Metabolic Disorder Study
The FDA has lifted the clinical hold placed on Viking Therapeutics Inc’s (NASDAQ:VKTX) trial of VK0214 in patients with X-linked adrenoleukodystrophy (X-ALD). …
Vicinity Motor Inks Distribution Deal With Family-Owned Bus Dealership Schetky
Vicinity Motor Corp (NASDAQ:VEV) has signed a distribution agreement with Schetky Bus and Van Sales to offer the Vicinity Lightning, Vicinity…
SpaceX Is Launching 10 Rockets For Each Launched By Its Main US Rival — Elon Musk Says ‘It’s Just A Start’
Elon Musk-led SpaceX has been prolific in sending its Falcon rockets to the International Space Station and the Tesla, Inc. (NASDAQ: TSLA) CEO says this is just a start.
The Daily Biotech Pulse: FDA Tentatively Approves Avadel’s Narcolepsy Drug, European Approval Broadens AstraZeneca’s Enhertu in Breast Cancer, Pharma Giants’ Earnings
Here's a roundup of top developments in the biotech space over the last 24 hours:
SCYNEXIS Highlights Presentation Of Data From Phase 3 CANDLE Nested Sub-Study
Data show that 71% of 24 patients with recurrent vulvovaginal candidiasis (RVVC) who failed to respond to a three-day regimen of fluconazole achieved a substantial reduction or complete elimination of signs
PharmaCyte Biotech Reports Interim Results in Malignant Ascites Mouse Model Study
PharmaCyte Biotech, Inc. (NASDAQ:PMCB), a biotechnology company focused on developing cellular therapies for cancer, diabetes, and malignant ascites using its signature live-cell encapsulation technology,
Infobird Co., Ltd Announces International Expansion With Singapore Based Channel Partner
Entry into Singapore Market Represents Company's Initial International Expansion Effort
BEIJING, July 19, 2022 /PRNewswire/ -- Infobird Co., Ltd (NASDAQ:IFBD) ("Infobird" or the
Hasbro Reports Mixed Q2 Results; Foreign Exchange Tampers Top Line Growth
Hasbro Inc (NASDAQ:HAS) reported second-quarter FY22 sales growth of 1% year-on-year, to $1.34 billion, missing the consensus of $1.37 billion. Segment…